$966M Talc Verdict Rocks J&J As Zantac, NEC, And Depo See Major Shifts East Of Eden Netflix [8YRQyD1ghDu]

alessandro tersigni This weeks Tort Talks covers the major rulings and developments shaping the mass tort sidney crosby iihf world championship landscape one week before MTMP:

Talcum Powder: A $966 million verdict against J&J in a California mesothelioma trial raises pressure ahead of the first ovarian cancer bellwether set to begin November 3.

Zantac: Oral arguments at the Second Circuit challenge the MDLs expert exclusion, a decision that could revive tens of thousands of claims and signal whats ahead for Tylenol.

NEC: A new case management conference is expected to reset the bellwether schedule after earlier dismissals, with a push for backup cases emploi to maintain trial momentum.

Depo-Provera: Case filings have doubled in just three months as a favorable ruling lets plaintiffs keep claims alive while awaiting the key preemption decision due before Thanksgiving.

Your complete mass tort briefing for the week in less than 10 minutes.

Contents of this video

00:00 Intro: Tort Talks with Joe Fantini

00:25 Talcum Powder: $966M Verdict and Ovarian Cancer Trial Preview

01:39 Zantac: Second Circuit Oral Arguments and Tylenol Parallel

03:54 NEC: Case Management Conference and Bellwether Framework

05:33 Depo-Provera: Doubling Filings and Positive Rulings for Plaintiffs

07:14 Closing: MTMP Preview and Next Weeks Updates